Mizuho set a $16.00 price objective on Akebia Therapeutics (NASDAQ:AKBA) in a report published on Friday, TipRanks reports. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.
Other equities analysts have also issued research reports about the company. BidaskClub raised Akebia Therapeutics from a strong sell rating to a sell rating in a research note on Friday, August 2nd. Zacks Investment Research raised Akebia Therapeutics from a sell rating to a hold rating in a research note on Friday, July 12th. HC Wainwright dropped their price objective on Akebia Therapeutics from $19.00 to $17.00 and set a buy rating for the company in a research note on Tuesday, August 6th. ValuEngine raised Akebia Therapeutics from a sell rating to a hold rating in a research note on Thursday, August 1st. Finally, JPMorgan Chase & Co. began coverage on Akebia Therapeutics in a research note on Thursday, May 2nd. They issued an overweight rating and a $12.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and four have given a buy rating to the stock. The company has a consensus rating of Hold and an average target price of $12.75.
NASDAQ:AKBA traded down $0.02 during mid-day trading on Friday, hitting $4.39. 999,774 shares of the company traded hands, compared to its average volume of 1,124,364. The company has a fifty day moving average of $4.18. Akebia Therapeutics has a one year low of $3.50 and a one year high of $10.45. The company has a debt-to-equity ratio of 0.06, a quick ratio of 1.15 and a current ratio of 1.71. The company has a market cap of $509.16 million, a price-to-earnings ratio of -1.80 and a beta of 1.43.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. First Quadrant L P CA bought a new position in shares of Akebia Therapeutics in the first quarter worth about $43,000. Aperio Group LLC bought a new position in shares of Akebia Therapeutics in the second quarter worth about $31,000. Advisor Group Inc. boosted its stake in shares of Akebia Therapeutics by 3,206.3% in the fourth quarter. Advisor Group Inc. now owns 9,919 shares of the biopharmaceutical company’s stock worth $54,000 after acquiring an additional 9,619 shares during the period. Jane Street Group LLC bought a new position in shares of Akebia Therapeutics in the fourth quarter worth about $57,000. Finally, Wedbush Securities Inc. bought a new position in shares of Akebia Therapeutics in the second quarter worth about $52,000. 70.45% of the stock is owned by hedge funds and other institutional investors.
Akebia Therapeutics Company Profile
Akebia Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its lead product candidate includes Auryxia, a ferric citrate to control the serum phosphorus levels in adult patients with chronic kidney disease (CKD), on dialysis (DD)-CKD, or the hyperphosphatemia indication (HIF); and vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to CKD in DD and non-dialysis patients.
Featured Story: Why is Cost of Capital Important?
Receive News & Ratings for Akebia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akebia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.